Axe Compute

Axe Compute Operating Cash Flow

The Operating Cash Flow of Axe Compute (AGPU) as of Oct 29, 2026 is -9.96 M USD. In the previous year, Operating Cash Flow was -11.96 M USD — a change of -16.70% (higher).

Operating Cash Flow

-9.96 MUSD

YoY

-16.70%

Last updated:

Operating Cash Flow of Axe Compute is 2025 -9.96 M USD. Operating Cash Flow of Axe Compute was 2024 -11.96 M USD. It decreases by -16.70% higher compared to the previous year.

The Axe Compute Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-5.29 M USD
Jan 1, 2019
-8.73 M USD
Jan 1, 2020
-12.26 M USD
Jan 1, 2021
-12.21 M USD
Jan 1, 2022
-12.37 M USD
Jan 1, 2023
-13.19 M USD
Jan 1, 2024
-11.96 M USD
Jan 1, 2025
-9.96 M USD
The Axe Compute Operating Cash Flow history
YEAROperating Cash FlowYoY
-9.96 MUSD-16.70%
-11.96 MUSD-9.35%
-13.19 MUSD+6.62%
-12.37 MUSD+1.33%
-12.21 MUSD-0.40%
-12.26 MUSD+40.37%
-8.73 MUSD+65.14%
-5.29 MUSD+18.57%
-4.46 MUSD+1.79%
-4.38 MUSD-41.48%
-7.49 MUSD+122.08%
-3.37 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Axe Compute Stock analysis

What does Axe Compute do? Predictive Oncology, Inc. generates revenue through its subsidiaries Helomics Holding Corporation and Skyline Medical Inc. Helomics applies artificial intelligence to patient tumor data to personalize cancer therapies and develop new-targeted therapies, offering CLIA-certified clinical testing for oncologists. Skyline Medical Inc. markets the STREAMWAY System, which automates medical fluid disposal, targeting hospitals and clinics globally. The company's products serve healthcare providers seeking advanced diagnostic and waste management solutions. Helomics focuses on personalized cancer treatment decisions using AI-driven analysis, while Skyline Medical Inc. provides automated fluid disposal systems. The STREAMWAY System is sold through domestic and international divisions to medical facilities requiring efficient waste handling. TumorGenesis Inc. supports laboratory-based tumor research, complementing Helomics' clinical offerings. The company's revenue streams include AI-based therapy personalization services and the STREAMWAY System sales. Healthcare providers, including oncologists and medical facilities, purchase these products to enhance treatment precision and operational efficiency. Subsidiaries operate under the parent company's structure, with Helomics handling AI applications and Skyline Medical managing medical device distribution. Axe Compute is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Axe Compute stock

Operating Cash Flow of Axe Compute is -9.96 M USD in 2025.

Operating Cash Flow of Axe Compute changed from -11.96 M USD to -9.96 M USD, representing a -16.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Axe Compute since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Axe Compute historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Axe Compute

All Key Metrics — Axe Compute